Current chemotherapy of schistosomiasis japonica in the Philippines.
For the past several decades, the drug being used for the treatment of schistosomiasis in the Philippines has been Stibophen. It is administered intramuscularly at a dose of 1 ml per 10 kg body weight with a maximum of 5 ml every other day after 2 initial daily smaller sensitivity doses at a total dose of 45 to 70 ml fof adult patients. In recent years, a number of drugs for the treatment of schistosomiasis have been developed. These were evaluated clinically either in the hospital or in field trials in Leyte. Unfortunately, none of these were found to be suitable for mass treatment on account of toxicity to prolonged course of treatment. In view of the pressing need for a safe and effective schistosomicidal agent, the search for a better drug is imperative.
D000328:Adult; D000814:Aniline Compounds / Q000627:therapeutic use; D000965:Antimony / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000031:analogs & derivatives; D004341:Drug Evaluation; D006801:Humans; D009560:Niridazole / Q000009:adverse effects / Q000627:therapeutic use; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000627:therapeutic use*; D013644:Tartrates / Q000627:therapeutic use
D000814:Aniline Compounds; D001557:Benzenesulfonates; D012556:Schistosomicides; D013644:Tartrates; D000965:Antimony; D003545:Cysteine; D009560:Niridazole